In:
Journal of the American Society of Nephrology, Ovid Technologies (Wolters Kluwer Health), Vol. 30, No. 10 ( 2019-10), p. 1870-1885
Abstract:
The role of B cells in renal ischemia-reperfusion injury (IRI) remains controversial, and the role of the recently discovered B cell subset, regulatory B cells, in renal IRI has not yet been studied. The authors demonstrated in mouse models that regulatory B cells attenuated renal IRI. They also found that treatment with anti-CD45RB with or without anti–Tim-1, which induces regulatory B cells and suppresses T cells, attenuated acute renal injury when given before IRI and facilitated renal recovery when given after IRI. The main mechanism underlying the anti-CD45RB–mediated reno-protective effects was induction of IL-10 + regulatory B cells. These findings provide insight into the role of regulatory B cells in renal IRI and suggest that anti-CD45RB may be a potential therapeutic strategy in renal IRI. Background Regulatory B cells are a newly discovered B cell subset that suppresses immune responses. Recent studies found that both anti-CD45RB and anti–Tim-1 treatments regulate immune responses by inducing regulatory B cells; however, the role of these cells in renal ischemia-reperfusion injury (IRI) is unknown. Methods Using mouse models, including T cell–deficient (RAG1 knockout and TCR α knockout) mice and B cell–deficient ( μ MT) mice, we investigated the effects of regulatory B cells and anti-CD45RB on IRI and the mechanisms underlying these effects. Results Adoptive transfer of regulatory B cells before or after IRI attenuated renal IRI. Anti-CD45RB treatment with or without anti–Tim-1 before IRI increased renal infiltration of CD19 + Tim-1 + regulatory B and regulatory T cells. Anti-CD45RB decreased serum creatinine levels, pathologic injury score, tubular apoptosis, and proinflammatory cytokines levels, whereas IL-10 levels increased. Following IRI, anti-CD45RB with or without anti–Tim-1 also induced regulatory B cells, improving renal function and tubular regeneration. In RAG1 knockout mice with B cell transfer, TCR α knockout mice, and wild-type mice with T cell depletion, anti-CD45RB increased regulatory B cells and attenuated IRI. However, anti-CD45RB did not attenuate IRI in RAG1 knockout mice with T cell transfer or μ MT mice and induced only mild improvement in wild-type mice with B cell depletion. Furthermore, B cell–deficient mice receiving B cells from IL-10 knockout mice (but not from wild-type mice) did not show renal protection against IRI when treated with anti-CD45RB. Conclusions Anti-CD45RB treatment attenuated acute renal injury and facilitated renal recovery after IRI through induction of IL-10 + regulatory B cells, pointing to anti-CD45RB as a potential therapeutic strategy in renal IRI.
Type of Medium:
Online Resource
ISSN:
1046-6673
,
1533-3450
DOI:
10.1681/ASN.2018101067
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2019
detail.hit.zdb_id:
2029124-3
Bookmarklink